StockData

EyePoint vs Outlook Therapeutics

EYPT and OTLK side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EYPT and OTLK compare

Outlook Therapeutics is the larger company, worth 3.4 times as much as EyePoint ($87.8M against $25.5M).

EyePoint scores higher on the StockData Score (6 against 4 for Outlook Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEYPTOTLK
Size and price
Market cap$25.5M$87.8M
Share price$0.296$0.361
Change, 1 year−97.4%−77.0%
Change, 5 years−98.2%−98.7%
Beta (5Y)3.313.72
Employees21417
StockData Score
Total score6 (better)4
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S9.1×–
P/B0.2×–
FCF yield−1063%–
Growth
Revenue growth (TTM)−94.6%–
Revenue growth, 5Y average−1.8%–
Profitability
Operating margin−11365%–
Net margin−10995%–
FCF margin−9727%–
Return on equity−149%–
Financial health
Debt / equity0.00–
Current ratio4.50 (better)0.81
Altman Z-score−11.43 (better)−40.77
Piotroski F-score2 (better)1
Dividends and buybacks
Buyback yield–−62.3%
Shareholder yield0.00% (better)−62.3%
Ownership
Held by institutions108%8.4%
Held by insiders0.96%28.5%
Insider net buying, 12 months−$1.9M$7.9M (better)
Short interest, % of float12.9%20.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.